VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue Clinical Trial

Official title:

Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00210392
• Other study ID #: IELSG25B
• Status: Terminated
• Phase: Phase 2
• First received: September 13, 2005
• Last updated: March 27, 2015
• Start date: July 2005
• Est. completion date: November 2007

Study information

• Verified date: March 2015
• Source: International Extranodal Lymphoma Study Group (IELSG)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: November 2007
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. histologically proven diagnosis of marginal zone B-cell lymphoma of MALT type arisen at any extranodal site

2. any stage (Ann Arbor I-IV)

3. relapsed or refractory disease pretreated with > 1 prior chemotherapy regimen and/or anti-CD20 immunotherapy

4. no evidence of histologic transformation to a high grade lymphoma

5. measurable or evaluable disease

6. age > 18 years

7. full recovery from previous therapy, with life expectancy of at least 6 months

8. ECOG performance status 0-2

9. for primary gastric localized H. pylori-positive disease at diagnosis:

1. persistent disease 1 year after documented H. pylori infection eradication

2. clinical, endoscopic (or histologic) evidence of progression at any time after H. pylori infection eradication

10. no prior chemotherapy, immunotherapy or radiotherapy in the last 6 weeks

11. no corticosteroids during the last 4 weeks, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms

12. adequate renal function (calculated or measured creatinine clearance >30 mL/minute), liver function (ASAT/ALAT <2,5 upper normal, total bilirubin <2,5x upper normal) and bone marrow function

13. no evidence of active opportunistic infections

14. no known HIV infection

15. no active HBV and/or HCV infection

16. no serious medical illness likely to interfere with participation in this clinical study

17. voluntary written informed consent before performance of any study-related procedure

18. female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria:

1. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1. (CIN1) or localized non-melanomatous skin cancer

2. other investigational drugs with 14 days before enrollment

3. evidence of symptomatic central nervous system (CNS) disease

4. severe impairment of bone marrow function (ANC <1.0x109/L, PLT <30x109/L within 14 days before enrollment), unless due to lymphoma involvement

5. evidence of = grade 2 peripheral neuropathy within 14 days before enrollment

6. known hypersensitivity to bortezomib, boron or mannitol

7. pregnant or lactating status, confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women

8. any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Mucosa-Associated Lymphoid Tissue

Intervention

Drug:
• Bortezomib (drug)
Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles

Locations

Country	Name	City	State
Switzerland	Oncology Institute of Southern Switzerland (IOSI)	Bellinzona

Sponsors (1)

Lead Sponsor	Collaborator
International Extranodal Lymphoma Study Group (IELSG)

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antitumor activity, in terms of overall response rate (ORR) i.e. sum of complete and partial responses		During treatment and one month after treatment completion	No
Secondary	Safety, as acute and long-term toxicity		18 months after treatment completion	Yes
Secondary	Response duration (RD) (time to relapse or progression) in responders		18 months after treatment completion	No
Secondary	Progression-free survival (PFS) (time to disease progression or death from lymphoma) in all patients		18 months after study completion	No

External Links

•   Click here for more information about this study